Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments
Source: Streetwise Reports  (2/2/19)
This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings. More >

Specialty Pharma 'Advances Pipeline' Ahead of Commercializing Lead Skin Therapy
Source: Streetwise Reports  (1/30/19)
LifeSci Capital reviewed the key takeaways from this Israeli firm's day-long research and development presentation. More >

Coverage Initiated on Developer of Therapies for Gastrointestinal Disorders
Source: Streetwise Reports  (1/30/19)
A ROTH Capital Partners report discussed this U.S.-based biopharma's two assets. More >

Anixa Doesn't Disappoint
Source: Daniel Carlson for Streetwise Reports  (1/29/19)
Daniel Carlson of Tailwinds Research explains why he has designated this company his 2019 stock of the year. More >

Early Data for Biotech's Pain Drug Candidate 'Show Promise'
Source: Streetwise Reports  (1/26/19)
An H.C. Wainwright & Co. report reviewed Phase 1b data for this nonopioid medication being developed for patients with severe pain. More >

Commercial Launch Planned for Schizophrenia Drug
Source: Streetwise Reports  (1/23/19)
A drug used to treat schizophrenic patients will launch commercially in February in the U.S. More >

Analyst: Reaction to Trial Data 'Unwarranted'
Source: Streetwise Reports  (1/23/19)
An analyst's note reviewed the recently announced study results in pancreatic cancer as well as the subsequent decline in stock price. More >

Analyst Shares 'Revelations from a Pooled Safety Analysis' of Pain Drug
Source: Streetwise Reports  (1/23/19)
An H.C. Wainwright & Co. report discussed the analgesic's safety profile and how it compares to an on-the-market competitor. More >

Phase 2 Study Begins for German Biopharma's Cancer Drug Candidate
Source: Streetwise Reports  (1/16/19)
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated. More >

Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data
Source: Streetwise Reports  (1/11/19)
Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report. More >

Healthcare Solutions Provider to Acquire Medical Software Firm
Source: Streetwise Reports  (1/10/19)
The merger will allow the Canadian company to expand its online technology platform. More >

Target Raised on Nutraceutical Firm After It Inks 'Marquee Partnership'
Source: Streetwise Reports  (1/9/19)
The agreement terms and benefits of the partnership to this pharmaceutical company were relayed in an H.C. Wainwright & Co. report. More >

Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic
Source: Streetwise Reports  (1/5/19)
The background and justification for the deal was covered in an H.C. Wainwright & Co. report. More >

Potential Tenbagger Biopharma Displays 'Strong Start to New Year'
Source: Streetwise Reports  (1/4/19)
A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock. More >

Texas-Based Biopharma Gets PDUFA Date for Lead Orphan Disease Asset
Source: Streetwise Reports  (1/2/19)
An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production. More >

Coverage Initiated on Pharma 'Leveraging Large Markets with Differentiated Products'
Source: Streetwise Reports  (12/29/18)
A Ladenburg Thalmann report outlined the investment thesis for this Colorado-based life sciences firm. More >

Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning
Source: Streetwise Reports  (12/24/18)
An H.C. Wainwright & Co. report provided an update on the Q3/18 activities and achievements of this company targeting NASH. More >

Coverage Initiated on Vaccine Developer with 'Transformational' Data Expected
Source: Streetwise Reports  (12/24/18)
A Ladenburg Thalmann report discussed this biotech's late-stage clinical assets in RSV and influenza. More >

Analyst: Biopharma Makes 'Right Call' in Stopping Combination Agent in Trial
Source: Streetwise Reports  (12/19/18)
A Mackie Research Capital Corp. note reviewed recent and upcoming developments in this immunotherapy developer's clinical study. More >

Urgent Update on Canadian Health Company Acquisition
Source: Clive Maund for Streetwise Reports  (12/18/18)
Technical analyst Clive Maund charts the potentially transformative acquisition of a medical software provider in Canada. More >

15 Reasons Why Hemp Producer Elixinol Should Be in Your Portfolio
Source: Fincom Investment Partners for Streetwise Reports  (12/17/18)
With the U.S. government legalizing hemp in the recently passed 2018 Farm Bill, Fincom Investment Partners profiles a hemp company whose largest market is the U.S. More >

Small-Cap Firm Announces Major Medical Technology Acquisition
Source: Ron Struthers for Streetwise Reports  (12/17/18)
Ron Struthers of Struthers Resource Stock Report profiles an innovative medical firm in Canada that just announced the acquisition of a medical technology firm, a move that will expand its reach across Canada. More >

Telehealth Services Provider's Positive Q3/18 Results Reflect 'Robust Growth Rate'
Source: Streetwise Reports  (12/12/18)
A William Blair report reviewed the firm's operational and financial numbers for the period. More >

Coverage Initiated on Tech Firm Servicing Healthcare Industry
Source: Streetwise Reports  (12/12/18)
Haywood Securities presented the thesis for investment in this company, including its growth drivers and continued focus on acquisition. More >

Strong Health Stock 'Ready to Commence New Upleg'
Source: Clive Maund for Streetwise Reports  (12/11/18)
Technical analyst Clive Maund analyzes a rapidly expanding company with medical clinics in British Columbia that is using advanced technology and AI. More >